Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Methicillin Resistant Staphylococcus Aureus Skin Infections Clear all
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 23, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

NCT00822276
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

NCT00289588
View directory record Official record
Conditions
Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis
Interventions
Mupirocin (drug)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
17 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2006 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT01209078
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
GSK1322322, Linezolid, GSK1322322 placebo, Linezolid placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Anniston, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 23, 2026, 2:42 AM EDT
Recruiting Phase 4 Interventional

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

NCT06982105
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effective Antibiotic Treatment of MRSA

NCT00388310
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Culture
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

NCT00352612
View directory record Official record
Conditions
Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
Interventions
clindamycin, cephalexin
Drug
Lead sponsor
Aaron Chen
Other
Eligibility
6 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Jul 23, 2026, 2:42 AM EDT
Not listed Phase 4 Interventional

Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence

NCT02566928
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
Interventions
2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol
Drug · Other · Behavioral
Lead sponsor
Clinical Directors Network
Network
Eligibility
7 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490
View directory record Official record
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
76
States / cities
Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

NCT01593761
View directory record Official record
Conditions
Skin Infection
Interventions
CG400549
Drug
Lead sponsor
CrystalGenomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Staph Household Intervention for Eradication (SHINE)

NCT02572791
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Chlorhexidine, Mupirocin, Household cleaning
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 2:42 AM EDT